Coverage
Filings
| Filing | Date |
|---|---|
| Transaction in Own Shares | 14 May 2008 |
| Treasury Stock | 6 May 2008 |
| 1st Quarter Results | 30 Apr 2008 |
| Treasury Stock | 28 Apr 2008 |
| Treasury Stock | 21 Apr 2008 |
| Treasury Stock | 14 Apr 2008 |
| Treasury Stock | 7 Apr 2008 |
| Treasury Stock | 2 Apr 2008 |
| Articles of Association of Novo Nordisk A/S |
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 1 Apr 2008 |
| Total voting rights | 1 Apr 2008 |
| Treasury Stock | 31 Mar 2008 |
| Treasury Stock | 17 Mar 2008 |